Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant factor VIII-Fc fusion protein - Kaifeng Pharmaceutical

Next Previous
Drug Profile

Recombinant factor VIII-Fc fusion protein - Kaifeng Pharmaceutical

Alternative Names: Factor-VIII - Kaifeng Pharmaceutical; FRSW 107

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kaifeng Pharmaceutical
  • Developer Jiangsu Gensciences; Kaifeng Pharmaceutical
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant fusion proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Haemophilia A

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Haemophilia-A(In children, Treatment-experienced) in China (Parenteral, Injection)
  • 18 Nov 2023 Jiangsu Gensciences plans a phase III trial in Haemophilia A (In infants, In children, Treatment-experienced) in China (Parenteral, Injection) in November 2023 (NCT06136507)
  • 10 Dec 2022 Jiangsu Gensciences plans to submit a Biologic License Application (BLA) to The National Medical Products Administration (NMPA) for Haemophilia A (Treatment, Prevention, In adolescents, In adults) in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top